Daily ePRO. Wearable data integration. Unified EDC and eCOA on one platform. Castor eliminates the separate eCOA vendor entirely, so your metabolic trial data flows directly where it needs to go.
Metabolic and obesity trials depend on patient-reported outcomes captured every day. Poor app design, burdensome login flows, and notification fatigue are the leading causes of ePRO dropout. Dropout in a long-duration GLP-1 trial is a protocol deviation, not just a missing data point.
Continuous glucose monitors, activity trackers, and smart scales generate data streams that need to flow into the EDC without manual transcription. Most platforms require custom integration work for each device. Castor supports direct data ingestion via open REST API.
Maintaining a parallel eCOA relationship means two contracts, two validation packages, two helpdesks, and a reconciliation process that adds weeks to every database lock. For a 52-week metabolic trial, that overhead compounds significantly.
GLP-1 and metabolic trials often run for 52 weeks or longer. Keeping patients engaged with the platform throughout requires a consumer-grade experience, not a clinical portal designed around site workflows.
GLP-1 and metabolic disease trials generate more daily patient data than almost any other therapeutic area. Weight measurements, dietary logs, physical activity, adverse events, and validated patient-reported quality-of-life outcomes must all be captured reliably, often for months or years. The industry default is to handle EDC and ePRO through separate vendors, creating a reconciliation problem that grows with every passing week of a long metabolic trial.
Castor Connect, our BYOD ePRO app, is designed around the patient experience first. Push notifications, intuitive interfaces, and short session formats drive 95%+ daily compliance in recent trials (with rates up to 98% in some studies). In a direct-to-patient RWE study of 1,000+ participants, Castor achieved greater than 90% compliance without site involvement. For daily diary studies in GLP-1 and metabolic programs, that number matters directly to data completeness and endpoint validity.
Source: eCOA Product Positioning
Castor’s API-first architecture allows you to securely pull structured data from continuous glucose monitors (CGMs), wearables, and aggregators directly into the EDC via our open REST API. Combine objective device telemetry with subjective patient-reported outcomes in a single, unified database, without building custom vendor silos. Sponsors can route device data from third-party aggregators or direct device APIs (covering ecosystems including Garmin, Fitbit, and Dexcom via aggregator) straight into Castor EDC.
Source: CDMS API Documentation
EDC and eCOA live in the same Castor database. Patient-reported outcomes flow directly into the study record with no data transfer, no reconciliation step, and no second validation package. One database. One audit trail. One database lock.
Castor comes pre-configured with 190+ validated instruments out of the box, including EQ-5D, SF-36, and PROMIS, the gold-standard assessments for metabolic trials. Deploy the instruments your protocol requires from day one, without the build time and licensing friction of legacy eCOA vendors.
Source: Product Positioning
GLP-1 is the fastest-growing therapeutic area in clinical research. Castor builds fast. 90% of studies go live in under 4 weeks, which means sponsors can respond to protocol changes and new indications without waiting months for platform configuration. The platform also delivers a proven 90%+ patient retention rate over long-term follow-up studies.
Obesity and metabolic disease studies increasingly recruit globally. The Castor platform is available in 80+ languages, supported by 24/7 multilingual patient support in 15-20 languages, with a single platform managing all markets and no per-country software instances required. Full regulatory compliance built in: FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, GDPR, and HIPAA validated across all study types and jurisdictions.
Obesity and metabolic disease studies hosted on Castor. Over 10,000 participants enrolled across the therapeutic area, including a 1,762-patient cardiometabolic health study and a 935-patient GLP-1 observational program.
Source: Castor platform data, verified 2026
In the BEACON and BOND endocrinology programs, Castor Catalyst automated EHR data ingestion and eliminated the manual transcription overhead that had consumed 40 hours of effort per patient. Time from patient enrollment to data appearing in the EDC dropped to just 1 hour.
Nearly 5,000 patients captured at a single centre (Radboud UMC), proving Castor can handle high-volume single-site oncology registries with complex longitudinal data requirements.
Yes. Castor Connect, our BYOD ePRO app, is designed for high-frequency data capture including daily diaries, weekly assessments, and event-driven reporting. The platform drives 95%+ daily compliance in recent trials (with rates up to 98% in some studies), and achieved greater than 90% compliance in a direct-to-patient RWE study of 1,000+ participants without site involvement. For metabolic trials where ePRO forms part of the primary endpoint, that level of compliance is a scientific requirement, not just an operational preference.
Yes. Castor ingests device and wearable data via our open REST API. Rather than locking you into a closed vendor ecosystem, the platform allows sponsors to route device data from third-party aggregators or direct device APIs straight into Castor EDC, covering ecosystems including CGMs, activity trackers, and smart scales. This provides a unified, real-time view of both objective metabolic telemetry and patient-reported ePRO data in a single database.
No. Castor’s EDC and eCOA are on the same platform and the same database. Patient-reported outcomes, including 190+ validated instruments covering the gold-standard metabolic assessments, are captured directly within the EDC without a data transfer step. This eliminates the reconciliation overhead and additional vendor relationship that separate eCOA tools require.
Castor is designed for trials of any duration. Long-duration study features include ongoing patient engagement tooling, notification management, visit schedule flexibility, and a patient app experience designed to reduce dropout over extended participation periods. The platform delivers a proven 90%+ patient retention rate over long-term follow-up studies, making it well-suited to the 52-week and multi-year timelines common in GLP-1 and metabolic disease programs.
